Two Promising Anti-cancer Development Programs
The company has a pipeline of novel oncology programs that target areas of unmet medical need, have potentially faster paths to market, and offer lower developmental risk by leveraging existing clinical and regulatory data, and using therapeutics with well understood safety profiles.
- Onco-D102 – Proprietary oral high dose vitamin D for Cancer Treatment.
Receptor Therapeutics has a program consisting of new methods of cancer treatment using Onco-D102, a potent, proprietary formulation of vitamin D. Research has shown that pre-treatment with high doses of vitamin D prior to cytotoxic drugs is highly synergistic, and that high pulse pre-chemotherapy treatment doses of vitamin D significantly enhances efficacy versus chemotherapy alone.With this knowledge, the Company signed an exclusive license for a patent estate covering pulsatile, high dose pre-treatment of cancers using vitamin D, and is developing a proprietary high dose formulation of the most potent form of vitamin D. This is the only vitamin D therapeutic that has demonstrated a near 50% increase in survival in prostate cancer patients when administered intermittently with Taxotere®. The Company is assembling a world class team in vitamin D cancer therapeutics to direct this exciting program.The clinical strategy for Onco-D102 involves a dose ranging study to optimize the dosing regimen and to finalize an indication for a registration trial. The Company has an aggressive, yet achievable goal of trial completion and submission of an NDA within three to four years.
- PoLi-PTX for Ovarian Cancer
PoLi is a proprietary and patented drug delivery technology, composed of a safe, biocompatible and biodegradable gel impregnated with existing chemotherapeutics such as paclitaxel (PoLi-PTX) or docetaxel (PoLi-DTX). The PoLi-PTX drug delivery system is being optimized for the intraperitoneal (IP) treatment of metastatic epithelial ovarian cancer (EOC), an indication of high unmet medical need.The most promising incremental improvement for the treatment of ovarian cancer is IP administration of chemotherapy. Ovarian cancer is one of the few cancers that tends to metastasize locally in the peritoneal cavity, and hence is an ideal indication for localized IP treatment. At the time of surgery the gel is applied to the peritoneal cavity in areas at high risk of tumor regrowth. The gel slowly degrades and releases the paclitaxel in a sustained and localized manner, thus providing high drug doses to tumor cells, while maintaining low systemic exposure. This drug delivery technology has the potential to provide dramatic improvements in the treatment of metastatic EOC, a disease that traditionally has a poor prognosis.Paclitaxel continues to be an important drug in oncology. Novel formulations of PTX that offer enhanced efficacy and safety are very valuable as evidenced by the recent acquisition of Abraxis Biosciences by Celgene for $2.9 billion. Celgene’s motivation for the purchase was for the product Abraxane®, a novel delivery formulation of PTX, which generated over $300 million in revenue in 2009. The Company believes that PoLi-PTX could also garner such attention.
Receptor Therapeutics – Product Pipeline Product Description Indication Status Onco-D102 Intravenous high dose vitamin D Cancer preclinical PoLi-PTX Paclitaxel-impregnated biodegradable gel Ovarian Cancer preclinical PoLi-DTX Docetaxel-impregnated biodegradable gel Cancer preclinical